Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Long-Term Investments (2016 - 2018)

Organogenesis Holdings (ORGO) has 3 years of Long-Term Investments data on record, last reported at $316.3 million in Q3 2018.

  • For Q3 2018, Long-Term Investments rose 1.48% year-over-year to $316.3 million; the TTM value through Sep 2018 reached $316.3 million, up 1.48%, while the annual FY2017 figure was $312.5 million, 0.81% up from the prior year.
  • Long-Term Investments reached $316.3 million in Q3 2018 per ORGO's latest filing, roughly flat from $314.8 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $316.3 million in Q3 2018 and bottomed at $310.0 million in Q4 2016.
  • Average Long-Term Investments over 3 years is $312.4 million, with a median of $312.1 million recorded in 2017.
  • Peak YoY movement for Long-Term Investments: grew 0.81% in 2017, then grew 1.48% in 2018.
  • A 3-year view of Long-Term Investments shows it stood at $310.0 million in 2016, then increased by 0.81% to $312.5 million in 2017, then rose by 1.21% to $316.3 million in 2018.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $316.3 million in Q3 2018, $314.8 million in Q2 2018, and $313.2 million in Q1 2018.